BOSTON, Dec. 22, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced its partnership with Carnegie-Mellon University (CMU) for an...
A Revolutionary ATCA/VME/VXI 3D-Flow Board: 512 Channels, >2,800 Programmable Operations—Scalable to >50,000 Operations on Each Dataset Arriving Every 25 ns...
Regulatory clearance of Bentrio in allergic rhinitis for Mainland ChinaNearly 200 million Chinese estimated to suffer from allergic rhinitisBentrio to...
Foundation to offer universal genomic testing for glioblastoma patients DURHAM, NC / ACCESS Newswire / December 18, 2025 / Today,...
SALT LAKE CITY, Dec. 18, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a...
SALT LAKE CITY, Dec. 18, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a...
CHICAGO and FORT WORTH, Texas, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”),...
DOYLESTOWN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical...
No treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following oral administration. MIAMI, FL /...
No treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following oral administration. MIAMI, FL /...
Watch the “What This Means” video here TAMPA, Fla. and LONDON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc...
Subject enrollment expected to begin in Q1 2026CDI-988 is the first oral broad-spectrum antiviral drug candidate for potential prevention of...
Subject enrollment expected to begin in Q1 2026CDI-988 is the first oral broad-spectrum antiviral drug candidate for potential prevention of...
12 early-career researchers will receive three years of support to carry out projects at the Institute for Systems Biology, University...
FRIENDSWOOD, Texas, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests...
All-RNA, non-viral, LNP-based PRINT™ platform is designed to develop safer, durable, one-time therapies for a broad range of unmet needsAddition...
Clinically meaningful lung function activity, measured by ppFEV1 and LCI2.5, with follow-up through 1 year at dose selected for Phase...
NESS ZIONA, Israel, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients...
VANCOUVER, British Columbia, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina” or the “Company”),...
Company Enters 2026 Positioned for Wide-Scale Deployment, Fueled by $50M Series A, 40+ Global Sponsors, and Measurable ROIBOSTON, Dec. 16,...